Ambros Therapeutics Raises $125 Million Series A to Advance Breakthrough Therapy for Rare Pain Disorder

Ambros Therapeutics, the newly launched clinical‑stage biotechnology company headquartered in Irvine, California, has secured an oversubscribed $125 million Series A financing to advance its lead investigational therapy for Complex Regional Pain Syndrome Type 1 (CRPS‑1), a debilitating rare disease with no FDA‑approved treatments. The significant capital raise marks a major step forward for the company as it prepares to initiate its pivotal Phase 3 registrational trial for neridronate, a non‑opioid bisphosphonate therapy that has shown promise in treating CRPS‑1 based on extensive experience in international markets.

The financing round was co‑led by RA Capital Management and Enavate Sciences, the life sciences investment platform of Patient Square Capital, highlighting strong investor confidence in Ambros’s strategy to address a high unmet need in chronic pain. The syndicate also attracted participation from a deep bench of dedicated life sciences backers, including Abiogen Pharma S.p.A., Janus Henderson Investors, Arkin Bio, Balyasny Asset Management, Transhuman Capital, and Adage Capital Partners LP, among others. This diverse group of institutional and strategic investors underscores broad support for Ambros’s clinical and commercial vision.

Ambros was founded to advance treatments for severe and underserved diseases, beginning with neridronate for CRPS‑1. The company’s launch follows the exclusive licensing of neridronate rights in North America from Italian partner Abiogen Pharma, which discovered and developed the drug. Neridronate has been used in Italy to treat CRPS and other conditions in more than 600,000 patients and has demonstrated a favorable safety and efficacy profile through prior Phase 3 studies. The FDA has granted neridronate Breakthrough Therapy, Fast Track, and Orphan Drug designations, positioning the program for an accelerated development pathway.

Ambros’s leadership team is spearheaded by Jay Hagan as Chief Executive Officer, bringing significant experience advancing biopharmaceutical programs from development into late‑stage clinical testing. Alongside Hagan, the executive team includes Gail Cawkwell, M.D., Ph.D. as Chief Medical Officer, Michael Cruse as Chief Operating Officer, Kunal Kishnani as Senior Vice President of Corporate Development, and Jennifer Lam as Senior Vice President of Finance and Administration. The Board of Directors features industry veterans such as Co‑Founder Vivek Ramaswamy and Keith Katkin as Chairman.

The Series A funding is earmarked to support the upcoming CRPS‑RISE Phase 3 clinical trial, which is anticipated to begin enrolling patients in the first quarter of 2026. This pivotal study aims to generate the data necessary for regulatory submissions and eventual commercialization in the United States, where no approved medicines currently exist for CRPS‑1. In addition to clinical development, the capital will fund regulatory preparations and pre‑commercial activities designed to ensure that Ambros is positioned to deliver meaningful impact to patients living with chronic pain.

CRPS‑1 is a rare, often severe pain condition estimated to affect approximately 65,000 new patients annually in the United States. Characterized by continuous and intense pain following injury without underlying nerve damage, the disorder can lead to significant functional impairment and a markedly reduced quality of life. The absence of FDA‑approved therapies has long presented a challenge for clinicians and patients alike, contributing to an urgent need for innovative treatment options. Ambros’s focus on a well‑characterized, non‑opioid therapy with established international use represents a promising approach to addressing this unmet need.

Investor interest in Ambros Therapeutics reflects a broader trend in the biotech sector toward funding programs that address rare diseases with high unmet medical needs and potential for accelerated regulatory pathways. With the backing of top‑tier life sciences investors and a seasoned leadership team, Ambros is now poised to advance neridronate through late‑stage development and, ultimately, toward potential U.S. approval. The success of this Series A round positions the company as an emerging player in the rare disease space, offering hope to patients and clinicians seeking effective alternatives to existing pain management approaches.